Acitretin in psoriasis: An overview of adverse effects - 07/09/11
Abstract |
Oral retinoids are among the drugs of choice for pustular and erythrodermic psoriasis. In addition, retinoids are effective in combination with other topical and systemic agents for the treatment of plaque-type psoriasis. Acitretin, the active retinoid metabolite, has replaced etretinate in retinoid therapy of psoriasis because of its more favorable pharmacokinetic profile, including a significantly shorter half-life. Retinoids, including acitretin, are potent teratogens, leading to strict requirements for pregnancy prevention during and after their use. Other retinoid side effects are generally preventable or manageable through proper patient selection, dose adjustments, and routine monitoring. Mucocutaneous side effects such as cheilitis and hair loss are the most common dose-dependent side effects, requiring dose reduction in some patients. Less common effects such as hepatotoxicity, serum lipid alterations, pancreatitis, and possible skeletal effects are also discussed. (J Am Acad Dermatol 1999;41:S7-12.)
Le texte complet de cet article est disponible en PDF.Plan
From the Department of Dermatology, University of Minnesota, Fridley. *Preventive Medicine Residency Program, University of California San Diego/San Diego State University, San Diego; and **Medical Director, Dermatology, Roche Laboratories, Inc., Nutley, NJ. |
|
This manuscript is based on a presentation given at the 5th European Congress on Psoriasis/7th International Psoriasis Symposium in Milan, Italy on September 2, 1998, with support from Roche Laboratories, Inc., Nutley, NJ. |
|
Reprint requests: H. Irving Katz, MD, Department of Dermatology, University of Minnesota, 7205 University Ave, NE, Fridley, MN 55432. |
|
0190-9622/99/$8.00 + 0 16/0/100482 |
Vol 41 - N° 3S
P. S7-S12 - septembre 1999 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?